Orient Pharma Co (ROCO:4166) Operating Margin %: 23.53% (As of Dec. 2025)


ROCO:4166 Orient Pharma Co Ltd ROCO:4166
56 GF Score
Price NT$27.20
GF Value NT$45.09
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co Operating Margin %?

Orient Pharma Co ROCO:4166 +5.02% 56 Operating Margin % is 23.53% as of Dec. 2025. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 956 Drug Manufacturers companies, Orient Pharma Co ranks better than 80.33% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Orient Pharma Co's Operating Income for the three months ended in Dec. 2025 was NT$104 Mil. Orient Pharma Co's Revenue for the three months ended in Dec. 2025 was NT$442 Mil. Therefore, Orient Pharma Co's Operating Margin % for the quarter that ended in Dec. 2025 was 23.53%.

The historical rank and industry rank for Orient Pharma Co's Operating Margin % or its related term are showing as below:

ROCO:4166' s Operating Margin % Range Over the Past 10 Years
Min: -134.75   Med: -34.64   Max: 19.07
Current: 19.07


ROCO:4166's Operating Margin % is ranked better than
80.33% of 956 companies
in the Drug Manufacturers industry
Industry Median: 7.58 vs ROCO:4166: 19.07

Orient Pharma Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Orient Pharma Co's Operating Income for the three months ended in Dec. 2025 was NT$104 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$267 Mil.


Orient Pharma Co  (ROCO:4166) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Orient Pharma Co Operating Margin % Related Terms


Orient Pharma Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co Operating Margin % Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.81 -8.15 3.12 14.22 19.07

Orient Pharma Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.86 18.80 16.33 15.94 23.53

ROCO:4166 vs ZTS, UTHR: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Pharma Co Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's Operating Margin % falls into.


ROCO:4166
56GF Score
Orient Pharma Co Ltd ROCO:4166
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Orient Pharma Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=267.062 / 1400.378
=19.07 %

Orient Pharma Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=103.939 / 441.808
=23.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 23.53% mean?
Orient Pharma Co (ROCO:4166) has a Operating Margin % of 23.53% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Orient Pharma Co and its competitors. According to the industry distribution chart, Orient Pharma Co ranks #188 out of 956 companies in the Drug Manufacturers industry, placing it in the top 19.7%.
Is Orient Pharma Co's Operating Margin % too high?
Orient Pharma Co's current Operating Margin % is 23.53%. The Drug Manufacturers industry median Operating Margin % is 7.58. Orient Pharma Co's value of 23.53% is 210.4% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #188 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #188 out of 956 companies for Operating Margin %. This places Orient Pharma Co in the top 20% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.58. Orient Pharma Co's value of 23.53% is 210.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Operating Margin % of 23.53% is 210.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Operating Margin % is 23.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Operating Margin % is 23.53% and 210.4% above the Drug Manufacturers industry median of 7.58. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Operating Margin % is 23.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Operating Margin %: 23.53%
  • GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
  • GF Score™: 56/100 with 2 warning signs
  • Industry Position: 210.4% above the Drug Manufacturers median (#188 of 956)

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score

Get the complete analysis for ROCO:4166

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.20
Price
NT$45.09
GF Value